Bank of New York Mellon’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $15.7M | Buy |
470,697
+129,572
| +38% | +$3.22M | ﹤0.01% | 1775 |
|
|
2026
Q1 | $7.15M | Buy |
341,125
+42,419
| +14% | +$955K | ﹤0.01% | 2115 |
|
|
2025
Q4 | $6.87M | Sell |
298,706
-26,139
| -8% | -$860K | ﹤0.01% | 2139 |
|
|
2025
Q3 | $9.77M | Sell |
324,845
-149,042
| -31% | -$4.47M | ﹤0.01% | 1945 |
|
|
2025
Q2 | $17.2M | Sell |
473,887
-222,274
| -32% | -$8.01M | ﹤0.01% | 1606 |
|
|
2025
Q1 | $25.2M | Sell |
696,161
-42,812
| -6% | -$1.78M | 0.01% | 1371 |
|
|
2024
Q4 | $31.1M | Sell |
738,973
-33,112
| -4% | -$1.64M | 0.01% | 1309 |
|
|
2024
Q3 | $42.9M | Sell |
772,085
-9,858
| -1% | -$502K | 0.01% | 1130 |
|
|
2024
Q2 | $32.1M | Sell |
781,943
-129,713
| -14% | -$5.54M | 0.01% | 1295 |
|
|
2024
Q1 | $42.6M | Sell |
911,656
-99,174
| -10% | -$4.68M | 0.01% | 1130 |
|
|
2023
Q4 | $48.3M | Buy |
1,010,830
+389,124
| +63% | +$15.1M | 0.01% | 1061 |
|
|
2023
Q3 | $22.2M | Sell |
621,706
-21,280
| -3% | -$843K | ﹤0.01% | 1492 |
|
|
2023
Q2 | $29.7M | Sell |
642,986
-8,724
| -1% | -$405K | 0.01% | 1325 |
|
|
2023
Q1 | $26.1M | Sell |
651,710
-34
| -0% | -$1.46K | 0.01% | 1400 |
|
|
2022
Q4 | $30.2M | Sell |
651,744
-83,966
| -11% | -$3.3M | 0.01% | 1307 |
|
|
2022
Q3 | $30.5M | Sell |
735,710
-58,322
| -7% | -$3M | 0.01% | 1245 |
|
|
2022
Q2 | $47.4M | Buy |
794,032
+39,000
| +5% | +$2.4M | 0.01% | 1024 |
|
|
2022
Q1 | $54.8M | Sell |
755,032
-94,511
| -11% | -$6.58M | 0.01% | 1032 |
|
|
2021
Q4 | $71.4M | Sell |
849,543
-14,802
| -2% | -$1.2M | 0.01% | 899 |
|
|
2021
Q3 | $78M | Buy |
864,345
+4,488
| +0.5% | +$406K | 0.02% | 825 |
|
|
2021
Q2 | $82M | Buy |
859,857
+37,942
| +5% | +$3.95M | 0.02% | 824 |
|
|
2021
Q1 | $93.6M | Buy |
821,915
+63,283
| +8% | +$8.62M | 0.02% | 736 |
|
|
2020
Q4 | $105M | Sell |
758,632
-13,757
| -2% | -$1.63M | 0.02% | 627 |
|
|
2020
Q3 | $63.5M | Buy |
772,389
+17,240
| +2% | +$1.43M | 0.02% | 776 |
|
|
2020
Q2 | $59.1M | Buy |
755,149
+50,733
| +7% | +$3.36M | 0.02% | 792 |
|
|
2020
Q1 | $31.3M | Buy |
704,416
+473,598
| +205% | +$24.6M | 0.01% | 1020 |
|
|
2019
Q4 | $9.86M | Buy |
230,818
+4,572
| +2% | +$189K | ﹤0.01% | 1978 |
|
|
2019
Q3 | $9.68M | Sell |
226,246
-1,960
| -0.9% | -$106K | ﹤0.01% | 1957 |
|
|
2019
Q2 | $14.5M | Sell |
228,206
-488
| -0.2% | -$31.1K | ﹤0.01% | 1747 |
|
|
2019
Q1 | $15.9M | Buy |
228,694
+20,768
| +10% | +$1.19M | ﹤0.01% | 1694 |
|
|
2018
Q4 | $9.04M | Buy |
207,926
+661
| +0.3% | +$36.1K | ﹤0.01% | 1964 |
|
|
2018
Q3 | $15.8M | Sell |
207,265
-397
| -0.2% | -$32.3K | ﹤0.01% | 1779 |
|
|
2018
Q2 | $16M | Buy |
207,662
+3,903
| +2% | +$252K | ﹤0.01% | 1740 |
|
|
2018
Q1 | $10.4M | Buy |
203,759
+28,142
| +16% | +$1.42M | ﹤0.01% | 1960 |
|
|
2017
Q4 | $8.15M | Sell |
175,617
-6,955
| -4% | -$341K | ﹤0.01% | 2088 |
|
|
2017
Q3 | $9.72M | Buy |
182,572
+6,736
| +4% | +$399K | ﹤0.01% | 2003 |
|
|
2017
Q2 | $10.9M | Sell |
175,836
-9,676
| -5% | -$583K | ﹤0.01% | 1909 |
|
|
2017
Q1 | $12.6M | Buy |
185,512
+10,450
| +6% | +$796K | ﹤0.01% | 1831 |
|
|
2016
Q4 | $12.3M | Buy |
175,062
+10,186
| +6% | +$723K | ﹤0.01% | 1847 |
|
|
2016
Q3 | $11.7M | Sell |
164,876
-6,560
| -4% | -$419K | ﹤0.01% | 1791 |
|
|
2016
Q2 | $8.38M | Sell |
171,436
-5,333
| -3% | -$345K | ﹤0.01% | 1941 |
|
|
2016
Q1 | $11.2M | Buy |
176,769
+433
| +0.2% | +$28.3K | ﹤0.01% | 1772 |
|
|
2015
Q4 | $19.8M | Buy |
176,336
+1,556
| +0.9% | +$156K | 0.01% | 1399 |
|
|
2015
Q3 | $16.8M | Buy |
174,780
+6,332
| +4% | +$725K | 0.01% | 1523 |
|
|
2015
Q2 | $17.2M | Buy |
168,448
+86,771
| +106% | +$6.74M | ﹤0.01% | 1583 |
|
|
2015
Q1 | $5.07M | Buy |
81,677
+16,627
| +26% | +$924K | ﹤0.01% | 2309 |
|
|
2014
Q4 | $2.85M | Sell |
65,050
-27,334
| -30% | -$1.25M | ﹤0.01% | 2624 |
|
|
2014
Q3 | $5.23M | Buy |
92,384
+62,424
| +208% | +$3.14M | ﹤0.01% | 2289 |
|
|
2014
Q2 | $1.34M | Buy |
29,960
+10,571
| +55% | +$435K | ﹤0.01% | 3144 |
|
|
2014
Q1 | $948K | Buy |
+19,389
| New | +$998K | ﹤0.01% | 3311 |
|
Other funds holding RARE
EHI
N
PAM
PFM
Bank of New York Mellon's RARE Position: Q2 2026 in Review
Bank of New York Mellon increased its Ultragenyx Pharmaceutical (RARE) stake by 38% in Q2 2026, buying an estimated $3.22M and bringing the position to 470,697 shares worth $15.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1775.
Bank of New York Mellon first reported a position in RARE in Q1 2014 and has held it in 50 quarters since. The position peaked at $105M in Q4 2020. 136 funds tracked by Wall St. Rank hold RARE as of Q2 2026.
- Bank of New York Mellon held 470,697 shares of Ultragenyx Pharmaceutical worth $15.7M as of Q2 2026.
- Bank of New York Mellon bought 129,572 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $3.22M.
- Ultragenyx Pharmaceutical made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1775 holding.
- Bank of New York Mellon first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 50 quarters since.
- Bank of New York Mellon's Ultragenyx Pharmaceutical position peaked at $105M in Q4 2020.
- 136 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.